NCT01708044CompletedPhase 1
A Phase 1, Randomized, Placebo-Controlled Single-Blind, Dose-Ranging, 4-Way Crossover Study to Evaluate the Effect of Different Fixed Pramlintide: Insulin Dose Ratios on Postprandial Glycemic Control in Subjects With Type 1 Diabetes Mellitus
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment
Study Overview
Brief Summary
To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Is 18 to 70 years old
- •Is male, or is female and meets all the following criteria:
- •Not breastfeeding
- •Negative pregnancy test result and, if of childbearing potential, must practice and be willing to continue to practice appropriate birth control
- •Has been diagnosed with type 1 diabetes mellitus for at least 1 year and not achieving glycemic goal while on MDI of insulin
- •Has HbA1c between 7.0% and 9.0%
- •Has been on MDI of regular insulin, at a dose not to exceed 10 units/breakfast for at least 3 months or has been on continuous subcutaneous insulin infusion (CSII), at a dose not to exceed 10 units/breakfast, for at least 3 months and is willing to switch to an MDI insulin regimen for 1 day prior to enrollment and through the study
- •Has a body mass index (BMI) <30 kg/m2
Exclusion Criteria
- •Has experienced recurrent severe hypoglycemia requiring assistance within 6 months before Visit 1 Screening
- •Has a history of hypoglycemia unawareness
- •Has a confirmed diagnosis of gastroparesis
- •Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications:
- •Any antihyperglycemic agent other than insulin
- •Drugs that directly affect gastrointestinal motility (e.g., anticholinergic agents such as atropine)
- •Drugs that slow the intestinal absorption of nutrients (e.g., α-glucosidase inhibitors.
- •Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
- •Hepatic disease
- •Renal disease
- •Gastrointestinal disease
- •Pulmonary disease
- •Organ transplantation
- •Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus)
- •Is currently treated or has been previously treated with SYMLIN/pramlintide or has participated in a SYMLIN/pramlintide clinical study within 3 months of Visit 1 (Screening).
- •Has any clinically significant laboratory findings or medical history that may affect successful completion of the study and/or personal well-being
- •Has donated blood within 2 months or is planning to donate blood during the study.
- •Has had a major surgery or a blood transfusion within 2 months
- •Has received any investigational drug within 1 month
- •Has known allergies or hypersensitivity to any component of study treatment.
- •Is an immediate family member of personnel directly affiliated with the study at the clinical study site, or is directly affiliated with the study at the clinical study site.
- •Is employed by Amylin Pharmaceuticals, Inc (Amylin) (that is an employee, temporary contract worker, or designee responsible for the conduct of the study).
Arms & Interventions
Pramlintide 6 mcg per unit of insulin dose
Experimental
The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
Intervention: Pramlintide acetate (Drug)
Pramlintide 9 mcg per unit of insulin dose
Experimental
The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
Intervention: Pramlintide acetate (Drug)
Pramlintide 12 mcg per unit of insulin dose
Experimental
The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
Intervention: Pramlintide acetate (Drug)
Placebo
Placebo Comparator
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment
Time Frame: AUC 0-3 hrs compared to Placebo
Secondary Outcomes
- Incremental AUC (0-3 h) of plasma glucagon(0-3 hrs compared to Placebo)
- Absolute AUC (0-3 h), peak plasma concentration (Cmax), Cave, and Tmax of glucagon of plasma glucose.(0-3 hrs compared to Placebo)
- PK of pramlintide(0-3 hrs compared to Placebo)
- Safety(0-3 hrs compared to Placebo)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Health Care for Type 1 Diabetes in Developing WorldType 1 DiabetesNCT01424046University of Pittsburgh50
Completed
Phase 1
A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp TrialDiabetes, Type INCT00810589Medical University of Graz30
Withdrawn
Phase 1
A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection TherapyDiabetes Mellitus, Type 1NCT02623452Eli Lilly and Company
Completed
Phase 1
A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection TherapyDiabetes Mellitus, Type 1NCT02703350Eli Lilly and Company30
Completed
Phase 2
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT00313183AstraZeneca12